Survodutide, Boehringer Ingelheim’s investigational dual GLP-1/glucagon agonist, has produced significantly greater weight loss than placebo in a phase 3 trial in adults with obesity without diabetes. In the randomized SYNCHRONIZE-1 study, mean weight reductions at week 76 were -12.2% with 3.6 mg and -13.0% with 6.0 mg versus -5.4% for placebo. The trial enrolled 725 participants and met both primary endpoints based on treatment-regimen estimands, with gastrointestinal events reported as the most common adverse reactions. Boehringer’s next steps include safety follow-through and regulatory positioning as the company aims to differentiate the drug in an increasingly crowded obesity class. Separately, real-world evidence continues to frame payer interest in GLP-1-based strategies: a retrospective study reported Zepbound use in adults over age 55 with obesity was associated with lower healthcare costs, with savings that nearly covered treatment costs by six months in the analysis.